Stephen Colbert does not have an MD. But he apparently has a keen understanding of clinical trials, perhaps because of his DFA – doctor of fine arts.
Colbert—or should we say Dr. Colbert?—reviewed the results of the JUPITER trial last night in the latest installment of “Cheating Death with Dr. Stephen T. Colbert, DFA.” That trial, you may recall, suggested that even people with normal cholesterol levels may benefit from the drug Crestor (rosuvastatin), if their C-reactive protein (CRP) levels (inflammation markers) were high.
Colbert’s analysis cut right to the chase: “This is a great breakthrough in the battle to find things to prescribe to people who don’t need them.”
“True, the drug costs $100 a month,” he later added. “But that is a small price to pay to not have the heart attack that there’s no way of knowing that you would have had.”
… So I’d like to suggest that Colbert launch The Colbert Journal of Medicine. … Or maybe we should just put his name forward for U.S. Food and Drug Administration commissioner.
Full details and hilarious Colbert Report clip at Sci Am.